Luca M M Janssen
Overview
Explore the profile of Luca M M Janssen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
45
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pokhilenko I, Gutierrez-Colosia M, Janssen L, Evers S, Paulus A, Drost R, et al.
PLoS One
. 2024 Jul;
19(7):e0306539.
PMID: 38959274
In the wake of the mental health crisis in children and adolescents, the coordination of education and mental health services has become a global priority. However, differing terminologies and classifications...
2.
Chan H, Janssen L, Wijnen B, Hiligsmann M, Majoie M, Evers S
Epilepsia
. 2023 Aug;
64(11):2861-2877.
PMID: 37545415
This study was undertaken to systematically identify and critically appraise all published full economic evaluations assessing the cost-effectiveness of nonpharmacological interventions for patients with drug-resistant epilepsy. The Population, Intervention, Comparison,...
3.
Pokhilenko I, Janssen L, Paulus A, Drost R, Hollingworth W, Thorn J, et al.
Appl Health Econ Health Policy
. 2023 Jan;
21(2):155-166.
PMID: 36622541
Background: Measuring objective resource-use quantities is important for generating valid cost estimates in economic evaluations. In the absence of acknowledged guidelines, measurement methods are often chosen based on practicality rather...
4.
Janssen L, Drost R, Paulus A, Garfield K, Hollingworth W, Noble S, et al.
Pharmacoeconomics
. 2021 Jun;
39(9):983-993.
PMID: 34169466
Background: While the methods for conducting health economics research in general are improving, current guidelines provide limited guidance regarding resource use measurement (RUM). Consequently, a variety of methods exists, yet...
5.
Pokhilenko I, Janssen L, Evers S, Drost R, Schnitzler L, Paulus A
Pharmacoeconomics
. 2021 Jun;
39(8):889-900.
PMID: 34121169
Background: Psychosocial (e.g., anxiety or behavior) problems lead to costs not only in the healthcare sector but also in education and other sectors. As psychosocial problems develop during the critical...
6.
Schnitzler L, Janssen L, Evers S, Jackson L, Paulus A, Roberts T, et al.
Int J Technol Assess Health Care
. 2021 Mar;
37:e43.
PMID: 33686927
AbstractThe rapid spread of the current COVID-19 pandemic has affected societies worldwide, leading to excess mortality, long-lasting health consequences, strained healthcare systems, and additional strains and spillover effects on other...
7.
Bremmers L, Evers S, Drost R, Janssen L, Pokhilenko I, Paulus A, et al.
J Ment Health Policy Econ
. 2021 Jan;
23(3):115-137.
PMID: 33411675
Background: The inclusion of indirect spillover costs and benefits that occur in non-healthcare sectors of society is necessary to make optimal societal decisions when assessing the cost effectiveness of healthcare...
8.
Pokhilenko I, Janssen L, Hiligsmann M, Evers S, Drost R, Paulus A, et al.
Pharmacoeconomics
. 2020 Oct;
39(1):99-108.
PMID: 33026633
Objectives: Mental and behavioural disorders (MBDs) and interventions targeting MBDs lead to costs and cost savings in the healthcare sector, but also in other sectors. The latter are referred to...
9.
Janssen L, Pokhilenko I, Evers S, Paulus A, Simon J, Konig H, et al.
Int J Technol Assess Health Care
. 2020 Jul;
:1-8.
PMID: 32715991
Background: Mental health disorders and their treatments produce significant costs and benefits in both healthcare and non-healthcare sectors. The latter are often referred to as intersectoral costs and benefits (ICBs)....